Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report

Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report

The effectiveness of the tyrosine kinase inhibitor ALK (TKI) for non-small cell lung cancer has been confirmed. However, resistance to ALK-TKIs seems inevitable. Mutations in the ALK kinase domain have been reported as an important mechanism of acquired resistance to ALK therapy. However, patients w...

全面介紹

書目詳細資料
Main Authors: Jiuzhou Zhao, Xiang Li, Ruizhe Fan, Yaping Qin, Zhizhong Wang, Bo Wang, Shaomei Li, Jianfeng Fan, Xinxin Wu, Hongxia Liu, Yuping Guan, Yinfeng Liang, Xiao Zhang, Yongjun Guo
格式: Article
語言:English
出版: Frontiers Media S.A. 2022-11-01
叢編:Frontiers in Pharmacology
主題:
non-small cell lung cancer (NSCLC)
next generation sequencing (NGS)
EML4-ALK
F1174L
S1189C
de novo mutation
在線閱讀:https://www.frontiersin.org/articles/10.3389/fphar.2022.1060460/full

因特網

https://www.frontiersin.org/articles/10.3389/fphar.2022.1060460/full

相似書籍